Billionaire Ken Fisher’s Top 13 Growth Stock Picks

9. Eli Lilly and Company (NYSE:LLY)

Fisher Asset Management’s Equity Stake: $4.04 Billion

Number of Hedge Funds Holding Stakes: 115

The American pharmaceutical giant Eli Lilly and Company (NYSE:LLY) has been discovering, developing, and marketing medicines since 1876. It stands out as one of the best growth stocks, boasting a robust pipeline of diabetes and weight loss drugs. Its GLP-1-approved drugs in Zepbound (weight loss) and Mounjaro (diabetes) continue to generate billions of dollars in revenues and are expected to be key growth drivers.

It also boasts of Kisunla, a drug poised to strengthen its prospects in the Alzheimer treatment segment. Eli Lilly and Company (NYSE:LLY) has also inked a strategic partnership with Atkins Oncology to develop radiopharmaceuticals and targeted cancer treatments. Additionally, the company has announced plans to invest $27 billion in four new manufacturing locations as it tries to ramp up production of key drugs amid strong market demand. Eli Lilly plans to avert the risk of losing sales due to strong demand by bolstering operations.

Strong product demand has been the catalyst behind robust financial results going by 2024 revenues increasing by 32% to $45.04 billion. Net income doubled to $10.6 billion as it also generated $8.8 billion in cash flow from operations. Strong financial results leave Eli Lilly and Company (NYSE:LLY) in a solid position to continue reinvesting in its pipelines to sustain long-term growth.